Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront for the Non-opioid Neuropathic Pain Treatment, NRD.E1, for Greater China and Singapore
Novaremed AG and NeuroFront Therapeutics (Hong Kong) Limited jointly announce the signing of an exclusive collaboration and commercialization agreement for Novaremed’s innovative non-opioid investigational drug, NRD.E1, being developed for the treatment of diabetes-related neuropathic pain and other neuropathic pain indications. Under the terms of the agreement, Novaremed is eligible to receive from NeuroFront over USD 130 million in option and exercise fees as well as development, regulatory and sales milestone payments plus royalties on net sales.
Under the terms of the agreement, Novaremed will grant NeuroFront an exclusive option to obtain exclusive development, commercialization and manufacturing rights to NRD.E1, Novaremed’s first-in-class, innovative non-opioid investigational drug candidate for the treatment of neuropathic pain. The agreement allows NeuroFront to develop and commercialize NRD.E1 as treatment of painful diabetic peripheral neuropathy (PDPN) and any other neuropathic pain indications in the Greater China territory (including Mainland China, Hong Kong, Macau, and Taiwan) and Singapore.
NeuroFront has the right to exercise its license option at its discretion, but no later than upon completion of the Phase 2b trial of NRD.E1 in PDPN, which will start patient enrollment in coming weeks.
In case NeuroFront successfully develops and registers NRD.E1 in additional neuropathic pain indications in the licensed territory, Novaremed is also eligible to receive additional development and regulatory milestone payments for each additional indication.
“We are very delighted collaborating with NeuroFront to advance our non-opioid neuropathic pain treatment for patients suffering from PDPN and other neuropathic pain indications in China. Currently, approved medications for PDPN provide inadequate pain relief and are associated with many intolerable side effects. Based on both preclinical and clinical data, we believe NRD.E1 has the potential to offer unique benefits and revolutionize the way PDPN is treated,” said Isaac Kobrin, MD, Executive Chairman of Novaremed. “NeuroFront’s development and commercial expertise and its focus on innovative CNS drugs is complementary to our expertise and an ideal fit for Novaremed.”
“There are up to 19 million patients suffering from PDPN in China, but no new innovative drug has been introduced in the market for more than 15 years. There exists a significant unmet medical need and hence a great opportunity for NRD.E1, a first-in-class, novel treatment that has already demonstrated clinical effectiveness in a Phase 2a clinical trial and subsequently received US FDA Fast Track Designation and NIH sponsorship for its Phase 2b trial,” said June Yan, CEO of NeuroFront. “NeuroFront is very excited to partner with Novaremed to change the lives of many PDPN patients in Greater China and Singapore.”
This partnership and the transaction were facilitated with the assistance of Cukierman and Company Investment House.
About NRD.E1 and the treatment of chronic pain
NRD.E1 is an orally active small molecule with a novel mechanism of action by modulating Lyn kinase and has patent protection until 2040. NRD.E1 is Novaremed’s lead drug candidate currently being developed to treat painful diabetic peripheral neuropathy (PDPN). Novaremed successfully completed three Phase 1 studies  and one double-blind, placebo-controlled Phase 2a dose-finding proof-of-concept study  in which NRD.E1 showed a clinically relevant reduction in patient-reported pain (measured as an improvement in mean neuropathic pain score) and was very well tolerated at all doses tested.
On the basis of these results, NRD.E1 has been granted Fast Track Designation by the US FDA and was selected by the National Institutes of Health (NIH) in the US as the only oral agent to be included in the NIH-HEAL (Help End Long-term Addiction) program. The NIH will sponsor and execute a 12-week, double-blind, placebo-controlled Phase 2b study in patients with moderate to severe PDPN in the US. Recruitment into this clinical trial will start in coming weeks.
NeuroFront is a China-based clinical stage neuroscience biotech company with a focus on developing and commercializing innovative neuroscience therapies to address unmet needs and improve patients' lives in China and Asia. NeuroFront was established by top-tier life sciences investors, including Nan Fung Life Sciences and Pivotal bioVenture Partners China, and is led by an elite team of neuroscience industry veterans with substantial and compelling expertise in China and globally in both R&D and the commercialization of CNS products. NeuroFront is building a portfolio of innovative, transformative CNS therapies that treat migraine, painful diabetic peripheral neuropathy, depression, ADHD, and other CNS diseases with high unmet medical needs. For more information: www.neurofrontrx.com.
Novaremed AG, a privately held clinical-stage biopharmaceutical company, is developing a pipeline of innovative medications for chronic pain management to address the high unmet medical need for better pain relief and as an alternative to opioids. Its lead product is NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action, has FDA Fast Track Designation and IND-approval to proceed with a Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy (PDPN). The earlier stage pipeline addressing chronic neuropathic pain includes the development candidates MP-101 (Phase 2 stage), and MP-103 (preclinical stage), targeting the unmet medical need of prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN). Novaremed Ltd (Israel) and Metys Pharmaceuticals AG (Switzerland) are fully owned subsidiaries of Novaremed AG, domiciled in Basel (Switzerland). For more information: www.novaremed.com.
 Tiecke E., Rainisio M., Guentert T., Müller S., Hochman L., Kaplan E., Mangialaio S. (2022). First-in-human single-ascending-dose, multiple-dose and food interaction studies of NRD.E1, an innovative non-opioid therapy for painful diabetic peripheral neuropathy. Clinical Pharmacology in Drug Development (CPDD). (https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.1103)
 Tiecke E., Rainisio M., Eisenberg E., Wainstein J., Kaplan E., Silverberg M., Hochman L., Mangialaio S. (2022). NRD.E1, an innovative non-opioid therapy for painful diabetic peripheral neuropathy – a randomized proof of concept study. European Journal of Pain. (https://onlinelibrary.wiley.com/doi/10.1002/ejp.1989)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact for Novaremed
Mark Altmeyer, Executive Member of the Board
Contact for NeuroFront
Bin Yao, VP of Operations and Commercialization
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bakken Energy Reaches Key Application Milestone for $1.7b Loan Guarantee From the U.S. Department of Energy28.9.2022 12:00:00 CEST | Press release
Bakken Energy, through its subsidiary Great Plains Hydrogen, LLC, has been invited by the U.S. Department of Energy’s Loan Programs Office (LPO) to submit a Part II application under the Title XVII Innovative Clean Energy Loan Guarantee Program. The invitation is an important milestone in Bakken’s process in applying for DOE financing for $1.7 billion of Bakken’s $2.35 billion clean hydrogen project. Established via Title XVII of the Energy Policy Act of 2005, the DOE-backed loan, if awarded after DOE reviews the Part II application and completes subsequent due diligence, will support the acquisition of the Great Plains Synfuels Plant in North Dakota and its redevelopment into a world class production facility with low-cost clean hydrogen. Achieving this invitation to the Part II process is a key milestone for Bakken in the Department of Energy’s LPO process. The invitation states that “while this invitation from the DOE LPO does not guarantee or imply that Great Plains Hydrogen, LLC w
Regnology Announces its 29 th Annual RegTech Convention on 29 th – 30 th November28.9.2022 09:00:00 CEST | Press release
Regnology, a leading software provider with an exclusive focus on regulatory reporting solutions has announced its 29th annual RegTech Convention, taking place on the 29th-30th November in Frankfurt, Germany and virtually. The convention will bring together nearly 2,000 delegates across regulatory authorities, supervisory agencies, and financial institutions to explore the evolving trends in regulation. The theme for this year’s convention is Regulation 3.0, which will be explored across 30 keynotes and panel discussions from leading industry experts and Regnology subject matter experts. Over thirty external speakers will discuss how the regulatory complexity for financial institutions can be reduced in view of a challenging global economic environment, the pressure to maximize cost efficiencies, and an evolving financial market landscape. Fredrik Reinfeldt, Swedish prime minister from 2006-2014, will address the current political and economic challenges in Europe and how it affects th
Cadmatic Acquires Italian Engineering Software Company CLA28.9.2022 09:00:00 CEST | Press release
The acquisition is a further step in fulfilling Cadmatic’s strong growth strategy, which sees the company more than tripling its size in coming years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005546/en/ Jukka Rantala (left) and Gian Mario Tagliarett (Photo: Business Wire) EPC contractors and plant owner-operators use CLA’s software to manage piping materials and piping supports, construction sites, multidisciplinary engineering data, online tenders, project planning and plant welding. CLA was established in 2001 and employs 22 staff at its office in Piacenza, 70 km south of Milan. “CLA is a perfect strategic fit for us. They have impressive references, especially in the key area of multinational EPC companies and our offerings have no overlapping functionalities. By integrating CLA’s materials and construction management products with Cadmatic’s design, engineering, and information management solutions, we can of
Mavenir Announces 2G, 4G and 5G Open RAN Radios Made in India28.9.2022 07:30:00 CEST | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced to have commenced the production of 2G, 4G and 5G Open RAN Radios for the OpenBeam™portfolio in India, for Indian and other prominent worldwide bands. OpenBeam offers an innovative radio portfolio, cost-efficient, intelligent radios that meet the critical demands placed on today’s networks including massive MIMO, mmWave and multi-band remote radio heads (RRHs) allowing improved network capacity as the network expands. The OpenBeam Open RAN radio solutions are available across all frequency bands and can be used for a wide range of use cases, including enterprises and public settings across urban or rural environments. Mavenir’s robust set of radio options address the needs of the CSPs to be agile and cost-efficient with low power consumption, low wind load, and built with integrated intelligence and automatio
Tigo Energy Surpasses One-Terawatt Hour of Monitored Solar PV Energy in Europe28.9.2022 07:00:00 CEST | Press release
Tigo Energy, Inc., the solar industry's leading Flex MLPE (Module Level Power Electronics) supplier, today announced that the solar energy monitoring function in the Tigo Energy Intelligence Solution has logged more than one Terawatt hour of photovoltaic energy generated by customer systems in the European market. Powered by the Tigo TS4 family of MLPE products, the Energy Intelligence Solution reports high-precision, module-level monitoring of solar installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220927006003/en/ The initial residential installation for The Ipv6 Company was in Galapagar, near Madrid. This 9.5kW system serves both home and office with a small data center. (Photo: Business Wire) With PV installations across Europe expected to grow by 40 GW in 2022, solar continues to take a leading position as the clean energy production method of choice throughout the region. With the Tigo Energy Intelligence (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom